Skip to content
Open access

In vitro activity of tizoxanide derivatives on Trypanosoma cruzi bloodstream trypomastigotes.

Oct 2026 · Bioorganic & Medicinal Chemistry Letters · pp. 130810 · 0 citations · 25 references
Medicine

Abstract

Chagas disease, which is transmitted by Trypanosoma cruzi parasites, remains a major neglected tropical disease for which there are limited treatment choices. In this study, we present the in vitro evaluation of 31 tizoxanide (TIZ) derivatives against the Y strain of T. cruzi bloodstream trypomastigotes. Several of the compounds exhibited significantly enhanced trypanocidal activity compared to benznidazole (BZ), the reference drug. At 4 °C, eight derivatives demonstrated IC₅₀ values ranging from 25 to 50 μM, up to four times more active than BZ. At physiological temperature (37 °C), these compounds exhibited enhanced potency, with IC₅₀ values as low as 1.9 μM and selectivity indices (SIs) of up to 77, indicating low cytotoxicity to host macrophages. The most promising of these compounds, 13, 19 and 21 exhibited superior efficacy to both BZ and TIZ, the key active metabolite of nitazoxanide (NTZ). In vitro DMPK analyses of selected front runner compounds reveal that halogenation of the phenyl ring provides analogues with significantly increased metabolic stability. Our in vitro findings demonstrate that analogues in this series are potent, metabolically stable and represent potential T. cruzi drug lead candidates, warranting further mechanistic and in vivo evaluation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.